ArticleAdvances in therapy2024

Risk for Mortality in High versus Low Antiparkinsonian Therapy Dose During the First Year of Parkinson's Disease: A Real-World Study.

Yael Barer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.